Healthcare, Pharma & Life Sciences

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) will hold one-on-one investor meetings at the Lake Street Capital Markets "BIG10" Conference in New York City on September 10, 2026.

The event runs in a one-on-one meeting format only. Profound will not offer a webcast, so investors who want access to management must attend the meetings in person.

Profound Medical sells interventional MRI therapies built around two platforms

The commercial-stage medical device company develops and markets interventional MRI (iMRI) procedures. Its flagship platform, TULSA-PRO, enables MRI-guided, incision-free prostate ablation. Physicians use the TULSA Procedure to see, ablate and confirm therapy in real time. The approach covers treatment from whole-gland to subtotal, hemi, multifocal and focal ablation.

Toronto – October 12, 2026 -- Profound Medical Corp. expects third-quarter 2026 revenue of $9.8 million to $10.0 million, roughly 45% to 47% above the Bloomberg mean analyst consensus of $6.78 million.

Revenue nearly doubles year over year and almost quadruples sequentially

The preliminary, unaudited range implies growth of approximately 85% to 89% from $5.3 million in the third quarter of 2025. Compared with $2.5 million in the second quarter of 2026, revenue is expected to rise approximately 292% to 300%.

The Nasdaq- and TSX-listed company expects gross margin to exceed 70% for the quarter, again above that threshold. Profound attributes the margin to progress in its commercial operations and scale.

Toronto – October 12, 2026 -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) has signed a co-education agreement with Telix Pharmaceuticals Limited (ASX:TLX; NASDAQ:TLX), giving it wider access to urologists in the U.S. and internationally through a strategic partner in prostate cancer imaging.

The agreement sets a framework to educate urologists, radiologists, nuclear medicine physicians and prostate cancer centers on how Telix's PSMA-targeting PET imaging agents, Gozellix and Illuccix, complement Profound's MRI-guided TULSA-PRO platform. The companies plan to cover the full prostate care continuum.

Calgary – October 12, 2026 -- XORTX Therapeutics Inc. has elected to voluntarily delist its common shares from the TSX Venture Exchange (TSXV), ending a dual listing it says no longer justifies its cost. The company will keep its primary listing on Nasdaq (XRTX) and its Frankfurt listing (ANU).

XORTX, a late-stage clinical pharmaceutical company developing therapies for gout and progressive kidney disease, will announce the timing of the delisting in a separate press release.

XORTX cites duplicate fees and regulatory complexity as reasons for leaving the TSXV

The company said a comprehensive evaluation concluded that the TSXV listing does not justify its costs and administrative requirements. It also said the different regulatory environments create challenges.

XORTX expects the delisting to deliver four outcomes:

Calgary – October 12, 2026 -- XORTX Therapeutics (NASDAQ: XRTX | TSXV: XRTX) has appointed Mika Grasso, 28, as co-CEO responsible for finance and public markets, and says it aims to advance its lead gout program, XRx-026, toward marketing approval over the next 18 months.

The company says the appointment follows a recent financing and growing investor interest. It is now restructuring its corporate and issuer status, re-initiating drug development programs and preparing regulatory filings for XRx-026. Risk disclosures in the release also refer to a voluntary delisting that may not be completed on the anticipated timeline, or at all.

Calgary – October 12, 2026 -- XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) has appointed Depesh Narotam, a financial services executive with more than 20 years of experience, to its board as an independent director effective July 27, 2026.

Board determines Narotam meets Nasdaq and Canadian independence standards

The board determined that Narotam, 43, is independent under applicable Nasdaq listing standards and Canadian securities laws. He also joins the board's Compensation, Governance and Nominating Committee.

Narotam is a resident of British Columbia, Canada.

Calgary – October 12, 2026 -- XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU) said board chairman Anthony Giovinazzo is stepping down from the board of directors, citing personal reasons and a wish to pursue other interests.

Giovinazzo leaves after several years as chairman and committee member

Giovinazzo led the board as chairman for the past several years and also served on key committees. Co-CEO Dr. Allen Davidoff credited him with leadership and ethics of the highest standards in both roles. Davidoff said management and the board extend their appreciation for his efforts.

The company did not name a successor chairman or give a departure date. The release also did not say whether Giovinazzo's committee seats will be refilled.

XORTX advances five programs in gout and kidney disease

The late-stage clinical pharmaceutical company is developing three clinically advanced products:

Calgary – October 12, 2026 -- XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX) has rescinded a US$2.5 million investor relations agreement with IR Agency LLC and recovered the full fee. The company is postponing its marketing push while it exits the TSX Venture Exchange.

XORTX terminates 90-day IR contract effective August 7, 2026

The agreement, dated May 13, 2026, ran for 90 days from May 18, 2026. It covered 10 marketing days of news distribution campaigns for an aggregate fee of US$2.5 million, payable in advance. The fee had been fully earned on receipt and was non-refundable.

Both parties agreed to rescind the arrangement, and all services under it have been discontinued. The funds were returned to XORTX in August 2026. The release cites both August 7 and August 14 as the return date.

Calgary – October 12, 2026 -- XORTX Therapeutics Inc. has re-engaged IR Agency LLC for investor relations and marketing services, following completion of its voluntary delisting from the TSX Venture Exchange.

XORTX restores IR Agency LLC consulting agreement on previously disclosed terms

The new consulting agreement carries substantially the same terms the company disclosed in news releases dated May 19, 2026 and August 28, 2026. The source gives no fee, share-based compensation or contract-length figures for the renewed engagement.

Delisting from TSX Venture Exchange precedes the renewed marketing push

The re-engagement comes after XORTX completed the delisting it had announced earlier. The company's filings reference ongoing compliance with Nasdaq listing standards, and its release states that Nasdaq has not approved or disapproved its contents.

Calgary – October 12, 2026 -- XORTX Therapeutics (NASDAQ: XRTX) plans to submit an Investigational New Drug application to the U.S. FDA in the fourth quarter of 2026 for its XRx-026 gout program, and estimates the program addresses a US$700M annual market opportunity.

XORTX targets an NDA filing in about one year, contingent on funding

The IND describes the company's clinical development plan for XORLOTM, its proprietary oxypurinol formulation, and its intention to file a New Drug Application after completing the two-part XRX-OXY-102 clinical trial. The trial is designed to characterize the pharmacokinetics and efficacy information the FDA needs to evaluate a future NDA.